Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology.
MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film.
MonoSol Rx focuses on transition of prescription drug delivery systems from pills to film. It has two FDA-approved products- Suboxone (buprenorphine and naloxone) sublingual film and Zuplenz (ondansetron) oral soluble film..
“Our alliance with MonoSol Rx will enable us to expand our family of pediatric products to help meet the needs of children for a variety of indications. We look forward to working with MonoSol Rx on the development of these products,” said Paul McGarty, President, Lupin Pharmaceuticals.
For patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms, PharmFilm technology provides a minimally invasive alternative to pills, injections, and gels, with the goal of helping patients adhere to their prescribed treatment regimens in order to improve their health.
The technology could offer potential to support pediatric patients in particular, many of whom have difficulty with the currently available oral or injectable dosing of needed medications.
“The agreement would be in line with the company’s focus on expanding into the specialty pharmaceutical market, and specifically, pediatric needs such as attention-deficit/hyperactivity disorder (ADHD),” Lupin said.
Lupin manufactures a wide range of branded & generic formulations, biotechnology products and APIs globally.
For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs 136,539 million ($ 2.09 billion) and Rs 22,607 million ($ 345 million) respectively.
MonoSol Rx is a specialty pharmaceutical company which provides PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs.
Lupin Pharmaceuticals, Inc. is headquartered in Baltimore, Maryland. Lupin is the 5 th largest pharmaceutical company in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016).